SCHEMBL1860727

SCHEMBL1860727

CS(=O)(=O)N1CCN(C(=O)c2cc3nc(Cl)nc(N4CCOCC4)c3o2)CC1

nearest known ligand 0.44

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 13/20 0.44
PIK3R1 P27986 3/20 0.44
PIK3CD O00329 8/20 0.42
MTOR P42345 5/20 0.42
PIK3CB P42338 8/20 0.41
SMN1; SMN2 Q16637 1/20 0.40
ABL1 P00519 1/20 0.39
BCR P11274 1/20 0.39
PIK3CG P48736 7/20 0.39
PARP1 P09874 1/20 0.39
PARP2 Q9UGN5 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
ALDH1A1 P00352 1/20 0.38
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23804682 0.86 SMN1; SMN2 (0.43) PIK3CAPIK3CDMTORPIK3CBSMN1; SMN2
SCHEMBL23804677 0.85 NPC1 (0.44) PIK3CAPIK3CDMTORPIK3CBSMN1; SMN2
SCHEMBL1858693 0.81 PIK3CA (0.55) PIK3CAPIK3R1PIK3CDMTORPIK3CB
SCHEMBL23804760 0.81 SMN1; SMN2 (0.42) PIK3CAPIK3R1MTORPIK3CBSMN1; SMN2
SCHEMBL1858883 0.79 SMN1; SMN2 (0.46) PIK3CAPIK3R1PIK3CDPIK3CBSMN1; SMN2
SCHEMBL189804 0.79 PIK3CA (0.61) PIK3CAPIK3R1PIK3CDMTORPIK3CB
SCHEMBL1856157 0.79 SMN1; SMN2 (0.46) PIK3CAPIK3R1MTORPIK3CBSMN1; SMN2
SCHEMBL1859229 0.78 SMN1; SMN2 (0.45) PIK3CAPIK3R1PIK3CDMTORPIK3CB
SCHEMBL23804783 0.78 SMN1; SMN2 (0.51) PIK3CAPIK3R1MTORPIK3CBSMN1; SMN2
SCHEMBL1859631 0.77 PIK3CA (0.73) PIK3CAPIK3R1PIK3CDMTORPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2046799-B1 PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM GENENTECH INC (US) 2017-07-19 EP disclosed
US-8450315-B2 Phosphoinositide 3-kinase inhibitor compounds and methods of use GENENTECH, INC. (US) 2013-05-28 US disclosed
US-20110105464-A1 PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE GENENTECH, INC. 2011-05-05 US disclosed
US-7846929-B2 Using 1-(4-((2-(aminopyrimidin-5-yl)-4-morpholinothieno(3,2-d)pyrimidin-6-yl)methyl)piperazin-1-yl)-2-(methylsulfonyl)ethanone; lipid kinase inhibitor; anticancer agents ; antiinflammatory agents; antidiabetic agents GENENTECH, INC. (US) 2010-12-07 US disclosed
EP-2046799-A1 PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Genentech, Inc. (US) 2009-04-15 EP disclosed
US-20080039459-A1 Phosphoinositide 3-kinase inhibitor compounds and methods of use PLRAMED LIMITED (GB) 2008-02-14 US disclosed
WO-2007127183-A1 PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM GENENTECH, INC. (US) 2007-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105464-A1 PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE PI4KB, PIK3CB, PIK3C2B PIK3CA 6/4885PIK3R1 25/4885PIK3CD 10/4885
US-20080039459-A1 Phosphoinositide 3-kinase inhibitor compounds and methods of use PIK3CA, PI4KB, PI4KA PIK3CA 1/4885PIK3R1 27/4885PIK3CD 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.